Welby Inc. (4438.T) develops and provides personal health record (PHR) platforms and digital health solutions that enable patients to manage medical data and support self-management of chronic conditions. The company operates primarily through two segments: Medical Solution Services, which delivers customized electronic health and medical record platforms developed in collaboration with pharmaceutical companies, medical device manufacturers, governments, and healthcare providers; and Welby MyKarte Services, featuring the free smartphone application "Welby MyKarte" for recording and visualizing metrics such as blood glucose levels, blood pressure, weight, exercise activity, medication adherence, and meals, with automated data integration from compatible devices and sharing capabilities with healthcare professionals via graphs, tables, and reports. These services target patients with lifestyle-related diseases including diabetes, hypertension, and obesity, as well as mental illness, autoimmune diseases, neurological disorders, rare diseases, oncology, and pain management; the company also conducts medical data surveys and operates web-based tools.
Founded in 2011 and headquartered at 1-11-1 Kyobashi, 4th Floor, KEPCO Real Estate Yaesu Building, Chuo-ku, Tokyo 104-0031, Japan, Welby focuses on patient-centered healthcare primarily in Japan, partnering with entities like Suzuken Co. Ltd., which increased its stake to a significant holding via a 2023 acquisition from Digital Garage Inc., and Chubu Electric Power Co. for PHR service expansion.
In recent developments, Welby entered a 2024 business alliance with Chubu Electric Power and Suzuken to accelerate PHR adoption through joint development of consumer healthcare apps and medical institution services, including a partial stake sale in MeDaCa Inc. to Suzuken; the company released Welby MyKarte app version 3.0.5 in 2025 with enhanced usability and historical data input features; and it hosted the "Rework Forum 2025" for HR and general affairs professionals, alongside ongoing co-development of disease-specific tools like Nikibi Log with Maruho Co. and MyKarte ONC with Chugai Pharmaceutical.